Approved for use through 07/31/2012, OMB 0891-0031 U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OME control number.

Substitute for form 1449/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	10/599697
	Filing Date	October 5, 2006
	First Named Inventor	Wagner, Jürgen et al.
	Art unit	1612
	Examiner Name	Webb, Walter E
Sheet 1 of 1	Affornay Oocket Number	PAT033714-US-PCT

	***************************************	NON PATENT LITERATURE DOCUMENTS	
Exeminer Initials*	Cita No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1,2
		Lee et al., "Protein kinase C isozymes as potential therapeulic targets in immune disorders," Expert Opin. Ther. Targets, Vol. 12(5), pp. 535-552, (2008).	
		Baier et at., "PKC inhibitors: potential in T cell-dependant immune diseases," Current opinion in Cell Biology, Vol 21, pp. 262-267, (2009).	
		Baler, Gottfried, "The PKC gene module: molecular biosystematics to resolve its T cell functions," Immunological Reviews, Vol. 192, pp. 64-79, (2003).	
		Birchall et al., "Ro 32-0432, a Selective and Orally Active Inhibitor Of Protein Kinase C Prevents T-Cell Activation," Journal of Pharmacology and Experimental Therapeutics, Vol. 268, No. 2, pp. 922-929, (October 1, 1993).	a
		Evenou et al., "The Potent Protein Kinase C-Selective Inhibitor AE8071 (Sofrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation," Journal of Pharmacology and Experimental Therapeutics, Vol. 330, No. 3, pp. 792-801, (Received March 6, 2009; accepted June 1, 2009).	a
		Wilkinson et al., "Research Communication Isoenzyme specificity of bisindolymaleimides, selective inhibitors of protein kinase C," Blochem. J., Vol. 294, pp. 335-337, (1993).	
·			
***************************************			
	***************************************		
	•		
*****************	***************************************		
Examir		Date   Considered	

Examiner

Signature

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance

\*EXAMINER: Initial in reference considered, whether of mix cliabor is in conformatice with the Considered. Include copy of this form with the next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1,98. The information is required to obtain or retain a benefit by the public which is to like (and by the

This collection of importation is required by 37 CFR 1, 96. The information is required to obtain or retain a demand of the judge which by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1,14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1459, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1469, Alexandria, VA 22313-1450.